Gilead Facing Multiple Claims of Purposefully Delaying Safer HIV Drug Alternatives
It has been alleged that Gilead Sciences, an HIV drugmaker, purposefully delayed the introduction of safer, life-saving medications in order to increase profits.
In 2001, Gilead received approval for the sale of HIV drugs containing the compound, tenofovir disoproxil fumarate (TDF). Unfortunately, TDF medications have been linked to severe kidney and bone injuries. However, numerous lawsuits, including one filed by the AIDS Healthcare Foundation, have alleged that Gilead had, in fact, developed a much safer HIV treatment compound, tenofovir alafemanide fumarate (TAF).
It is further alleged that Gilead purposefully delayed the introduction of the safer TAF drugs, despite Gilead’s knowledge of the injuries being caused by the TDF drugs, in order to reap extended profits from Gilead’s drug patents on the TDF drugs (at the height of usage, Gilead’s TDF drugs were earning over $10 billion in annual sales). This has allegedly resulted in tens of thousands of reports of severe injuries.
If you are an HIV patient that was treated with Atripla, Complera, Stribild, Truvada, or Viread, you may be wrongly suffering from kidney injuries (including acute kidney injury, chronic kidney disease, renal failure, or related injuries), or bone injuries (including fractures, osteoporosis, osteopenia or related injuries).